Tecan Group Ltd
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments, Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, NGS reagents, immunoassays and antibodies, … Read more
Tecan Group Ltd (TCHBF) - Net Assets
Latest net assets as of June 2025: $1.28 Billion USD
Based on the latest financial reports, Tecan Group Ltd (TCHBF) has net assets worth $1.28 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.94 Billion) and total liabilities ($656.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.28 Billion |
| % of Total Assets | 66.12% |
| Annual Growth Rate | 14.1% |
| 5-Year Change | 95.64% |
| 10-Year Change | 225.71% |
| Growth Volatility | 190.19 |
Tecan Group Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Tecan Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tecan Group Ltd (2013–2024)
The table below shows the annual net assets of Tecan Group Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.44 Billion | +6.41% |
| 2023-12-31 | $1.35 Billion | -0.65% |
| 2022-12-31 | $1.36 Billion | +10.84% |
| 2021-12-31 | $1.22 Billion | +66.96% |
| 2020-12-31 | $733.65 Million | +11.32% |
| 2019-12-31 | $659.07 Million | +7.62% |
| 2018-12-31 | $612.41 Million | +11.28% |
| 2017-12-31 | $550.34 Million | +12.99% |
| 2016-12-31 | $487.08 Million | +10.53% |
| 2015-12-31 | $440.67 Million | +657.16% |
| 2014-12-31 | $58.20 Million | -82.69% |
| 2013-12-31 | $336.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tecan Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 200.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.11 Billion | 77.46% |
| Common Stock | $1.28 Million | 0.09% |
| Other Comprehensive Income | $351.17 Million | 24.47% |
| Total Equity | $1.44 Billion | 100.00% |
Tecan Group Ltd Competitors by Market Cap
The table below lists competitors of Tecan Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Expressway Company Limited
PINK:JEXYF
|
$2.03 Billion |
|
Hilton Grand Vacations Inc
NYSE:HGV
|
$2.03 Billion |
|
Page Industries Limited
NSE:PAGEIND
|
$2.03 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
$2.03 Billion |
|
Eaglerise Electric & Electronic China Co Ltd Class A
SHE:002922
|
$2.03 Billion |
|
Hyundai Steel
KO:004020
|
$2.03 Billion |
|
Haitian International Holdings Limited
OTCGREY:HAIIF
|
$2.03 Billion |
|
3Peak Inc
SHG:688536
|
$2.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tecan Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,348,910,000 to 1,435,331,000, a change of 86,421,000 (6.4%).
- Net income of 67,664,000 contributed positively to equity growth.
- Dividend payments of 38,320,000 reduced retained earnings.
- Share repurchases of 28,934,000 reduced equity.
- New share issuances of 1,358,000 increased equity.
- Other comprehensive income increased equity by 71,158,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $67.66 Million | +4.71% |
| Dividends Paid | $38.32 Million | -2.67% |
| Share Repurchases | $28.93 Million | -2.02% |
| Share Issuances | $1.36 Million | +0.09% |
| Other Comprehensive Income | $71.16 Million | +4.96% |
| Other Changes | $13.49 Million | +0.94% |
| Total Change | $- | 6.41% |
Book Value vs Market Value Analysis
This analysis compares Tecan Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $202.52 | x |
| 2016-12-31 | $0.00 | $202.52 | x |
| 2017-12-31 | $47.18 | $202.52 | x |
| 2018-12-31 | $52.05 | $202.52 | x |
| 2019-12-31 | $55.22 | $202.52 | x |
| 2020-12-31 | $60.98 | $202.52 | x |
| 2021-12-31 | $99.43 | $202.52 | x |
| 2022-12-31 | $106.17 | $202.52 | x |
| 2023-12-31 | $105.21 | $202.52 | x |
| 2024-12-31 | $112.30 | $202.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tecan Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.24%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.48x
- Recent ROE (4.71%) is below the historical average (10.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 13.58% | 11.76% | 0.83x | 1.39x | $12.05 Million |
| 2014 | 11.13% | 10.07% | 0.72x | 1.53x | $660.03K |
| 2015 | 12.97% | 12.98% | 0.69x | 1.46x | $13.08 Million |
| 2016 | 11.20% | 10.77% | 0.69x | 1.51x | $5.83 Million |
| 2017 | 12.09% | 12.13% | 0.68x | 1.46x | $11.51 Million |
| 2018 | 11.54% | 11.91% | 0.69x | 1.40x | $9.46 Million |
| 2019 | 11.10% | 11.49% | 0.68x | 1.43x | $7.26 Million |
| 2020 | 14.13% | 14.19% | 0.66x | 1.51x | $30.32 Million |
| 2021 | 9.93% | 12.85% | 0.47x | 1.63x | $-830.50K |
| 2022 | 8.92% | 10.59% | 0.54x | 1.56x | $-14.65 Million |
| 2023 | 9.79% | 12.29% | 0.52x | 1.54x | $-2.82 Million |
| 2024 | 4.71% | 7.24% | 0.44x | 1.48x | $-75.87 Million |
Industry Comparison
This section compares Tecan Group Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tecan Group Ltd (TCHBF) | $1.28 Billion | 13.58% | 0.51x | $2.03 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |